2024
ALL-408 Unveiling the Shadows: Thiamine Deficiency Manifesting As Sudden-Onset Blindness in a Patient With Leukemia
Ramachandran S, Stempel J, Podoltsev N, Mahajan A. ALL-408 Unveiling the Shadows: Thiamine Deficiency Manifesting As Sudden-Onset Blindness in a Patient With Leukemia. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s268. DOI: 10.1016/s2152-2650(24)01106-6.Peer-Reviewed Original ResearchWernicke's encephalopathyThiamine deficiencyB-ALLHematologic malignanciesDiagnostic challengePhiladelphia chromosome-positive B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaTreated with hyper-CVADHigh index of suspicionPrevent permanent neurological damageDasatinib dose reductionSudden onset blindnessIndex of suspicionAcute lymphoblastic leukemiaLoss of vibratory sensationPh+ B-ALLCerebrospinal fluid analysisSevere neurological dysfunctionCancer-directed therapyPermanent neurological damageVitamin B1 levelsAtypical neurological findingsHyper-CVADOphthalmologic examBilateral blindness
2022
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
Gupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.Peer-Reviewed Case Reports and Technical NotesMyeloid neoplasmsBiologic disease-modifying agentsTumor necrosis factor inhibitorsTyrosine kinase inhibitor imatinibNecrosis factor inhibitorsAutoimmune rheumatic diseasesDisease-modifying agentsKinase inhibitor imatinibTyrosine kinase inhibitorsMiddle-aged malesRheumatic diseasesFactor inhibitorsPatients' qualityFavorable outcomeHematologic malignanciesInhibitor imatinibBeta rearrangementInfliximabConcurrent useKinase inhibitorsCancer diagnosisPatientsNeoplasmsAppropriate casesInhibitors